Tenaya Therapeutics, Inc. (TNYA) Financial Analysis & Valuation | Quarter Chart
Tenaya Therapeutics, Inc. (TNYA)
TNYAPrice: $1.24
Fair Value: 🔒
🔒score
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus ... more
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for ... more
Description
Shares
| Market Cap | $205.63M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Faraz Ali |
| IPO Date | 2021-07-30 | CAGR | — |
| Employees | 97 | Website | www.tenayatherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TNYA chart loading...
Fundamentals
Technicals
| Enterprise Value | $219.84M | P/E Ratio | -1.36 |
| Forward P/E | -1.7 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.43 |
| P/CF Ratio | -2.77 | P/FCF Ratio | -2.8 |
| EPS | $-0.94 | EPS Growth 1Y | -47.3% |
| EPS Growth 3Y | -72.04% | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.95% | ROA | -0.9% |
| ROCE | -1.06% | Current Ratio | 4.64 |
| Quick Ratio | 4.64 | Cash Ratio | 4.26 |
| Debt/Equity | 0.14 | Interest Coverage | — |
| Altman Z Score | -3.96 | Piotroski Score | 1 |